[Intravitreal ranibizumab (Lucentis®) in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy].
METHODS
A 25 year old patient with high myopia diagnosed of metachronic choroidal neovascularisation in both eyes secondary to punctate inner choroidopathy leading to visual impairment and metamorphopsia. First eye was treated with four injections of ranibizumab after photodynamic therapy and the second eye only with charge dose of ranibizumab, reaching inactivity with good final visual acuity in both eyes.


CONCLUSIONS
Ranibizumab is useful in the treatment of this illness. Prospective studies are needed to investigate the usefulness of a combination with adjuvant therapies such as photodynamic therapy.
Valverde Megías
A
A
Licenciatura en Medicina, Unidad de Patología Macular, Hospital Clínico San Carlos, Madrid, España. valverdmegias@hotmail.com
Arriola Villalobos
P
P
Reche Frutos
J
J
Donate López
J
J
Calvo González
C
C
García Feijoo
J
J
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D015862:Choroid Diseases / Q000150:complications*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab